816 related articles for article (PubMed ID: 28480062)
21. Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival.
Somma F; Stoia V; Serra N; D'Angelo R; Gatta G; Fiore F
PLoS One; 2019; 14(5):e0216935. PubMed ID: 31141552
[TBL] [Abstract][Full Text] [Related]
22. Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis.
Rognoni C; Ciani O; Sommariva S; Bargellini I; Bhoori S; Cioni R; Facciorusso A; Golfieri R; Gramenzi A; Mazzaferro V; Mosconi C; Ponziani F; Sacco R; Trevisani F; Tarricone R
BMC Cancer; 2018 Jul; 18(1):715. PubMed ID: 29976149
[TBL] [Abstract][Full Text] [Related]
23. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
[TBL] [Abstract][Full Text] [Related]
24. The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence.
Cerreto M; Cardone F; Cerrito L; Stella L; Santopaolo F; Pallozzi M; Gasbarrini A; Ponziani FR
Curr Oncol; 2023 Sep; 30(10):8774-8792. PubMed ID: 37887533
[TBL] [Abstract][Full Text] [Related]
25. Current treatment options for hepatocellular carcinoma.
Eugen K
Klin Onkol; 2020; 33(Supplementum 3):20-25. PubMed ID: 33213161
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules.
Gutierrez JA; Gish RG
Transl Cancer Res; 2013 Dec; 2(6):460-471. PubMed ID: 26504748
[TBL] [Abstract][Full Text] [Related]
27. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives.
Mosconi C; Cappelli A; Pettinato C; Golfieri R
World J Hepatol; 2015 Apr; 7(5):738-52. PubMed ID: 25914774
[TBL] [Abstract][Full Text] [Related]
28. The treatment path in hepatocellular carcinoma.
El-Serag HB; Zhu AX; Johnson MS
Clin Adv Hematol Oncol; 2017 Aug; 15 Suppl 9(8):1-20. PubMed ID: 29036035
[TBL] [Abstract][Full Text] [Related]
29. Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification.
Golfieri R; Bargellini I; Spreafico C; Trevisani F
Liver Cancer; 2019 Mar; 8(2):78-91. PubMed ID: 31019899
[TBL] [Abstract][Full Text] [Related]
30. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
31. Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.
Eggert T; Greten TF
Digestion; 2017; 96(1):1-4. PubMed ID: 28605745
[TBL] [Abstract][Full Text] [Related]
32. Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial.
Chauhan N; Bukovcan J; Boucher E; Cosgrove D; Edeline J; Hamilton B; Kulik L; Master F; Salem R
JMIR Res Protoc; 2018 Aug; 7(8):e11234. PubMed ID: 30111528
[TBL] [Abstract][Full Text] [Related]
33. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
[TBL] [Abstract][Full Text] [Related]
34. Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments.
Cappelli A; Pettinato C; Golfieri R
J Hepatocell Carcinoma; 2014; 1():163-82. PubMed ID: 27508185
[TBL] [Abstract][Full Text] [Related]
35. Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients.
Facciorusso A; Licinio R; Muscatiello N; Di Leo A; Barone M
World J Hepatol; 2015 Aug; 7(16):2009-19. PubMed ID: 26261690
[TBL] [Abstract][Full Text] [Related]
36. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
[TBL] [Abstract][Full Text] [Related]
37. Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies.
Makary MS; Khandpur U; Cloyd JM; Mumtaz K; Dowell JD
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32679897
[TBL] [Abstract][Full Text] [Related]
38. Pretransplant Intra-arterial Liver-Directed Therapy Does Not Increase the Risk of Hepatic Arterial Complications in Liver Transplantation: A Single-Center 10-Year Experience.
Kallini JR; Gabr A; Ali R; Abouchaleh N; Riaz A; Baker T; Kulik L; Caicedo J; Salem R; Lewandowski RJ
Cardiovasc Intervent Radiol; 2018 Feb; 41(2):231-238. PubMed ID: 28900709
[TBL] [Abstract][Full Text] [Related]
39. Goals and targets for personalized therapy for HCC.
Couri T; Pillai A
Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
[TBL] [Abstract][Full Text] [Related]
40. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
